Could a malaria pill tame discoid lupus?
NCT ID NCT07557927
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether dihydroartemisinin, a drug used for malaria, can help treat discoid lupus erythematosus (DLE), a chronic skin condition causing red, scaly patches. Researchers will compare two doses of the drug to a standard lupus treatment (hydroxychloroquine) in 100 adults over 24 weeks. The goal is to see if it reduces skin severity and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dihydroartemisinin tablets
What this could lead to
If it works, this could offer a new treatment option for discoid lupus, a chronic skin condition, potentially with fewer side effects than current therapies.
What could go wrong
This is an early Phase 2 trial with only 100 people, so results may not apply to everyone. It's also not a cure—patients would still need ongoing management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DISCOID LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
-
Hangzhou Third People's Hospital
Hangzhou, Zhejiang, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
-
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
-
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China